Hepatobiliary transporters in drug-induced cholestasis: a perspective on the current identifying tools
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Impaired bile formation leads to the accumulation of cytotoxic bile salts in hepatocytes and, consequently, cholestasis and severe liver disease. Knowledge of the role of hepatobiliary transporters, especially the bile salt export pump (BSEP), in the pathogenesis of cholestasis is continuously increasing. AREAS COVERED: This review provides an introduction into the role of these transport proteins in bile formation. It addresses the clinical relevance and pathophysiologic consequences of altered functions of these transporters by genetic mutations and drugs. In particular, the current practical aspects of identification and mitigation of drug candidates with liver liabilities employed during drug development, with an emphasis on preclinical screening for BSEP interaction, are discussed. EXPERT OPINION: Within the potential pathogenetic mechanisms of acquired cholestasis, the inhibition of BSEP by drugs is well established. Interference of a new compound with BSEP transport activity should raise a warning sign to conduct follow-up experiments and to monitor liver function during clinical development. A combination of in vitro screening for transport interaction, in silico predicting models, and consideration of physicochemical and metabolic properties should lead to a more efficient screening of potential liver liability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751 · cited 1×
“MRP1 (ABCC1) is involved in the hepatocellular efflux of drug conjugates (glutathione, glucuronide, and sulfate), and MRP3 (ABCC3) and MRP4 (ABCC4) are implicated in the efflux of bile salts, and the transport of the antiretroviral drugs lamivudine, zidovudine and stavudine [28].”
BackgroundDanan, G., & Benichou, C. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90101-6 · Cited by 1,481 · cited 1×
“Various causality assessment methods have been proposed [14-16], and the key elements for attributing liver injury to a drug include i) exposure to a drug must precede the onset; ii) exclusion of underlying disease causes; iii) improvement of liver injury after cessation of a drug (de-challenge); and iv) recurrence af…”
BackgroundHighly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells
Si-Tayeb, K., Noto, F. K., Nagaoka, M., Li, J., Battle, M. A., Duris, C., North, P. E., Dalton, S., & Duncan, S. A. (2010) · Hepatology · doi:10.1002/hep.23354 · Cited by 1,282 · cited 2×
“Further, new developments in the area of cellular systems such as induced pluripotent stem cells hold promise to study the pathogenesis and genetics of DILI [109].”
BackgroundIdiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Bile salt transporters: molecular characterization, function, and regulation
Trauner, M., & Boyer, J. L. (2003) · Physiological Reviews · doi:10.1152/physrev.00027.2002 · Cited by 999 · cited 3×
“Of note, cholestatic-related agents such as pro-inflammatory cytokines, hormones and drugs may promote deregulation of transporter protein genes, and hereditary mutations in hepatobiliary transporter proteins may reduce transporter expression and functionality [19].”
BackgroundDrug-Induced Acute Liver Failure: Results of a U.S. Multicenter, Prospective Study
Reuben, A., Koch, D. G., & Lee, W. M. (2010) · Hepatology · doi:10.1002/hep.23937 · Cited by 772
Yamanaka, S. (2009) · Cell · doi:10.1016/j.cell.2009.03.034 · Cited by 659 · cited 1×
“Furthermore, they allow assessing the impact of a genetic polymorphism on systems involved in drug metabolism and transport and its relationship with drug adverse events [112].”
BackgroundFattinger, K. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.114667 · Cited by 509
Bile Acid Transporters: Structure, Function, Regulation and Pathophysiological Implications
Alrefai, W. A., & Gill, R. K. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9289-1 · Cited by 500 · cited 2×
“Bile acid homeostasis is the result of a coordinated regulation of genes involved in bile acid synthesis, detoxification and transport [19,20,22,23].”
BackgroundHay, D. C., Zhao, D., Fletcher, J., Hewitt, Z. A., McLean, D., Urruticoechea-Uriguen, A., Black, J. R., Elcombe, C., Ross, J. A., Wolf, R., et al. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0718 · Cited by 441 · cited 1×
“As such, they have the potential to replace hepatocyte cell lines in drug toxicity screening assays [111], providing also an opportunity to identify potential effects of new drug candidates on specific disorders [101].”
BackgroundDawson, S., Stahl, S., Paul, N., Barber, J., & Kenna, J. G. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040758 · Cited by 343
Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism
Eloranta, J. J., & Kullak-Ublick, G. A. (2005) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2004.09.019 · Cited by 260
Insight into hepatotoxicity: The troglitazone experience†
Watkins, P. B. (2005) · Hepatology · doi:10.1002/hep.20598 · Cited by 45 · cited 2×
“In March 2000, troglitazone was withdrawn from the market [136].”
Background
Cited by
Cheng, P. T. W., Kaltenbach, R. F., Zhang, H., Shi, J., Tao, S., Li, J., Kennedy, L. J., Walker, S. J., Shi, Y., Wang, Y., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01256 · Cited by 61
A Pillar and Perfusion Plate Platform for Robust Human Organoid Culture and Analysis
Kang, S., Kimura, M., Shrestha, S., Lewis, P., Lee, S., Cai, Y., Joshi, P., Acharya, P., Liu, J., Yang, Y., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202302502 · Cited by 44
Metadata
- Authors
- de Lima Toccafondo Vieira, M., & Tagliati, C. A.
- Venue
- Expert Opinion on Drug Metabolism & Toxicology
- Publisher
- Informa Healthcare
- Published
- 2014-03-04
- Volume
- 10
- Issue
- 4
- Pages
- 581-597
- ISSN
- 1742-5255 (ISSN-L)
- 1744-7607
- OpenAlex
- W2118254089
- Cited by
- 36
- References
- 13
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.